A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease

A blood-based assessment of preclinical disease would have huge potential in the enrichment of participants for Alzheimer’s disease (AD) therapeutic trials. In this study, cognitively unimpaired individuals from the AIBL and KARVIAH cohorts were defined as Aβ negative or Aβ positive by positron emis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashton, Nicholas J., Nevado-Holgado, Alejo J., Barber, Imelda S., Lynham, Steven, Gupta, Veer, Chatterjee, Pratishtha, Goozee, Kathryn, Hone, Eugene, Pedrini, Steve, Blennow, Kaj, Schöll, Michael, Zetterberg, Henrik, Ellis, Kathryn A., Bush, Ashley I., Rowe, Christopher C., Villemagne, Victor L., Ames, David, Masters, Colin L., Aarsland, Dag, Powell, John, Lovestone, Simon, Martins, Ralph, Hye, Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365111/
https://www.ncbi.nlm.nih.gov/pubmed/30775436
http://dx.doi.org/10.1126/sciadv.aau7220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365111/
https://www.ncbi.nlm.nih.gov/pubmed/30775436
http://dx.doi.org/10.1126/sciadv.aau7220

Ejemplares similares